Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Magic mushroom mystery: is the 'Trip' essential for benefits?

NCT ID NCT06768944

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study aims to find out whether the intense subjective experience caused by psilocybin (the active ingredient in magic mushrooms) is necessary for its positive after-effects. 128 healthy adults will receive either a high or low dose of psilocybin, combined with either a placebo or risperidone (a drug that dampens psychedelic effects). Researchers will then compare changes in mood, stress, and behavior between groups to see if blocking the 'trip' reduces any benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psilocybin (high and low dose) and risperidone
What this could lead to
If it works, this could help scientists understand whether the psychedelic experience itself is necessary for psilocybin's lasting benefits, potentially guiding future therapies.
What could go wrong
This is an early Phase 2 study in healthy adults, not patients. It is small and designed to test a mechanism, not to treat any disease. Results may not apply to real-world therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals of all sexes, gender identities, and ethnicities * Ages 18 to 65 years of age at the time of screening * Ability to read/write in English * Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation Exclusion Criteria: * Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests * Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder * Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder * Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II * Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics * Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study * Current or recent (within 12 weeks) participation in a clinical trial involving medication administration * Cognitive impairment (Folsetin Mini Mental State Exam score \< 24) * A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery). * Suffered a traumatic brain injury with one of the following symptoms Loss of consciousness \>30min Alteration of consciousness/mental state \>24h Post-traumatic amnesia \>1 day Glasgow Coma Scale (best available score in first 24 hours) \<13 * Any other circumstances that, in the opinion of the investigators, compromises participant safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Investigating the importance of the subjective psychedelic experience are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fractures, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 4N1, Canada

    Contact Email: •••••@•••••